BioNTech

• A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

  Collaborator, Phase 2, Not yet recruiting, 80 people, 13 Oct 2026

• A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  Collaborator, Phase 1/2, Recruiting, 55 people, 28 Sept 2026

• A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  Phase 3, Recruiting, 736 people, 26 Jan 2026

• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  Phase 3, Recruiting, 558 people, 15 Sept 2025

• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  Phase 3, Recruiting, 621 people, 2 Dec 2024

• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  Phase 2/3, Recruiting, 1,580 people, 2 Dec 2024

• NCT06683352

  Phase 1/2, Completed, 1,353 people, 12 Nov 2024

• NCT06449222

  Phase 2, Active, not recruiting, 83 people, 7 Jun 2024

• NCT06449209

  Phase 2, Active, not recruiting, 110 people, 7 Jun 2024

• A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  Collaborator, Phase 3, Recruiting, 480 people, 1 Apr 2024

• NCT06178991

  Phase 3, Completed, 8,795 people, 21 Dec 2023

• A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

  Collaborator, Phase 1, Active, not recruiting, 8 people, 28 Sept 2023

• NCT06018337

  Collaborator, Phase 3, Active, not recruiting, 541 people, 30 Aug 2023

• NCT05142189

  Phase 1, Recruiting, 320 people, 2 Dec 2021

• NCT04101357

  Phase 1/2, Terminated, 54 people, 24 Sept 2019

• NCT04083599

  Collaborator, Phase 1/2, Active, not recruiting, 350 people, 10 Sept 2019

• NCT03219450

  Collaborator, Phase 1, Recruiting, 15 people, 17 Jul 2017

Sources: clinicaltrials.gov

• No association between Epstein-Barr Virus serostatus and infection-related mortality in 9,429 British adults: a UK Biobank study

  Consulting or advice, Fees or honoraria, Grants or research support, 17 Sept 2026

• Radiology considerations for the PREMIUM study: a multicenter randomized controlled trial of abbreviated MRI versus ultrasound for liver cancer screening in cirrhosis

  Grants or research support, 6 Sept 2026

• A comprehensive German claims data analysis of care pathways, risk factors and comorbidities among acetylcholinesterase inhibitor initiators in Alzheimer's disease

  Consulting or advice, Fees or honoraria, Board or leadership role, 31 Aug 2026

• Medial temporal ageing-related tau astrogliopathy below 66 years is associated with neurodegeneration

  Consulting or advice, Fees or honoraria, Board or leadership role, 3 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

• MON-524 The Impact of SGLT2 Inhibitors on Adverse Genitourinary Effects in Prostate Cancer Survivors With Diabetes

  ENDO 2025 abstract, 23 Oct 2025